登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Fc epsilon RI alpha >FCA-H82E3

Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag™ (MALS & BLI verified)

分子别名(Synonym)

FCER1A,FCE1A,FcERI

表达区间及表达系统(Source)

Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag (FCA-H82E3) is expressed from human 293 cells (HEK293). It contains AA Val 26 - Gln 205 (Accession # P12319-1).

Predicted N-terminus: Val 26

Request for sequence

蛋白结构(Molecular Characterization)

Fc epsilon RI alpha Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 24.6 kDa. The protein migrates as 50-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Fc epsilon RI alpha SDS-PAGE

Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

Fc epsilon RI alpha SEC-MALS

The purity of Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag (Cat. No. FCA-H82E3) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

Fc epsilon RI alpha ELISA

Immobilized Human IgE Fc, His Tag (Cat. No. IGE-H52H9) at 1 μg/mL (100 μL/well) can bind Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag (Cat. No. FCA-H82E3) with a linear range of 0.02-0.6 μg/mL (QC tested).

Protocol

 

活性(Bioactivity)-BLI

Fc epsilon RI alpha BLI

Loaded Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag (Cat. No. FCA-H82E3) on SA Biosensor, can bind Immunoglobulin E, Human Plasma with an affinity constant of 1.92 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A) is also known as Fc-epsilon RI-alpha (FcERI), IgE Fc receptor subunit alpha, FCE1A. FCER1A contains two Ig-like (immunoglobulin-like) domains. FCER1A binds to the Fc region of immunoglobulins epsilon and is a high affinity receptor. FCER1A is responsible for initiating the allergic response, which binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines. FCER1A plays a central role in allergic disease, coupling allergen and mast cell to initiate the inflammatory and immediate hypersensitivity responses that are characteristic of disorders such as hay fever and asthma.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Fc epsilon RI alpha靶点信息
英文全称:IgE Fc receptor, alpha-subunit
中文全称:IgE-Fc片段受体α亚基
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:0详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定